Ipamorelin: What the Evidence Says About This Selective GH Secretagogue

What Is Ipamorelin?

Ipamorelin is a synthetic five-amino-acid peptide that stimulates growth hormone release. It is distinguished from other GH-releasing peptides by its selectivity: it raises GH without significantly affecting cortisol, prolactin, or ACTH at standard doses.

Ipamorelin belongs to the growth hormone-releasing peptide (GHRP) family, which mimics ghrelin by binding to the GHS-R1a receptor (growth hormone secretagogue receptor) on pituitary cells. What distinguishes ipamorelin from its relatives (GHRP-6, GHRP-2, and hexarelin) is its hormonal selectivity. At doses that produce substantial GH release, ipamorelin does not significantly elevate cortisol, prolactin, or ACTH (Raun et al., 1998).

Developed by Novo Nordisk in the 1990s, ipamorelin reached Phase II clinical trials for post-operative ileus (delayed gut recovery after abdominal surgery) but was not commercialized. It has since become one of the most widely discussed peptides in communities focused on GH elevation for recovery and anti-aging purposes.

Who this page is for, and who it isn’t for

This page is for readers who want to understand ipamorelin’s pharmacology, the evidence supporting its effects, and where the research falls short. It is written for researchers, clinicians, and informed readers evaluating the literature.

This page is not a prescribing guide, a purchase recommendation, or medical advice. Ipamorelin is not FDA-approved for any human therapeutic use.

How Ipamorelin Is Thought to Work

Ipamorelin acts on the ghrelin receptor to stimulate pituitary GH release, but with notably less impact on other hormonal systems than related compounds.

GHS-R1a receptor activation

Ipamorelin binds to the ghrelin receptor (GHS-R1a) on pituitary somatotroph cells. This triggers a signaling cascade involving phospholipase C activation, inositol triphosphate (IP3) production, intracellular calcium release, and ultimately GH vesicle exocytosis.

The result is a pulsatile release of growth hormone that amplifies the body’s natural GH secretion pattern without fundamentally altering it.

Why selectivity matters

The distinguishing pharmacological feature of ipamorelin is its dose-dependent specificity:

• At standard doses (~1 μg/kg), it produces a robust GH pulse with no measurable increase in cortisol, prolactin, or ACTH
• This contrasts with GHRP-6, which raises cortisol and provokes significant hunger
• It also contrasts with GHRP-2, which can elevate both cortisol and prolactin
• Even at supratherapeutic doses, ipamorelin’s cortisol-raising effect is minimal compared to other GHRPs

(Raun et al., 1998)

This selectivity is clinically relevant. Cortisol elevation is catabolic and counterproductive for recovery and body composition goals. Prolactin elevation can cause unwanted effects including gynecomastia with chronic exposure. By avoiding these off-target effects, ipamorelin presents a cleaner hormonal profile than most of its class.

Preserved GH pulsatility

Unlike exogenous GH injection (which creates a supraphysiological, non-pulsatile GH spike), ipamorelin works within the body’s feedback system. The GH release it triggers is still subject to somatostatin inhibition, meaning GH pulses remain physiological in shape and negative feedback mechanisms are preserved.

Why it pairs with GHRH analogs

Ipamorelin’s ghrelin-mimetic mechanism is distinct from GHRH analogs like CJC-1295 and sermorelin, which act on GHRH receptors. These two pathways converge on pituitary somatotrophs in a synergistic manner. Combining them produces a GH pulse significantly larger than either compound alone. This is the pharmacological rationale for the widely discussed CJC-1295 + ipamorelin combination.

What the Research Shows

GH release in humans

In a Phase I study, intravenous ipamorelin (0.01–1 μg/kg) produced dose-dependent GH release in healthy male volunteers. GH peaked approximately 40 minutes post-injection and returned to baseline within 2–3 hours. Notably, even at the highest dose tested, cortisol and prolactin remained unchanged from baseline (Hansen et al., 1999).

Comparative studies showed ipamorelin produced GH release comparable to GHRP-6 at equivalent doses, but without the cortisol spike, appetite stimulation, or prolactin elevation.

Post-operative ileus trial

The most advanced clinical application studied was post-operative ileus — delayed return of gut motility after abdominal surgery. A Phase IIb trial (n=114) evaluated ipamorelin infusion in patients following abdominal surgery. Results showed some promise for accelerating gut recovery, but clinical development was discontinued, reportedly for commercial rather than safety reasons (Greenwood-Van Meerveld et al., 2007).

This trial is notable because it provides human safety data beyond single-dose pharmacology studies.

Body composition (animal data)

Animal studies demonstrate that chronic ipamorelin administration produces increased lean body mass, decreased fat mass, and improved bone mineral density, consistent with elevated GH/IGF-1 axis activation.

In growth hormone-deficient swine, ipamorelin over 15 days increased body weight gain with preferential lean mass accretion (Raun et al., 1998). Human body composition trials have not been published.

Bone density (animal data)

In ovariectomized rats (a model for postmenopausal osteoporosis), chronic ipamorelin treatment increased bone mineral density and improved bone microarchitecture. The effect was dose-dependent and associated with elevated IGF-1 levels (Svensson et al., 2000).

Important limitations

While ipamorelin has human pharmacokinetic and safety data, it lacks published human trials demonstrating efficacy for body composition, anti-aging, or recovery outcomes. The clinical evidence is stronger than for many peptides (the POI trial provides real-world safety data), but substantially weaker than for FDA-approved compounds like semaglutide or tesamorelin.

What Ipamorelin Has Been Studied For (Summary)

Based on available research:

• Selective GH release without cortisol/prolactin elevation: demonstrated in humans
• Body composition improvement: demonstrated in animals; no published human trials
• Bone density: demonstrated in animal models of osteoporosis
• Post-operative gut recovery: Phase IIb trial showed some promise
• Sleep quality: suggested by the general GH-sleep literature and community reports, but not directly studied for ipamorelin
• Recovery and tissue repair: inferred from GH/IGF-1 elevation, not directly studied

Community-Reported Protocols

The following reflects commonly discussed protocols. Ipamorelin is not FDA-approved for any human use. This information is included for reference and is not medical advice.

Standalone protocol

• Reported dose: 200–300 mcg per injection
• Reported frequency: 1–3 times daily
• Most commonly described timing: before bed (to amplify the natural nocturnal GH surge), morning fasted, or post-exercise
• Reported cycle length: 8–12 weeks, followed by a break. Some describe continuous use with periodic blood work.

Combined with CJC-1295 (no DAC / Mod GRF 1-29)

• Ipamorelin: 200–300 mcg
• Mod GRF 1-29: 100–200 mcg
• Described as combined in the same syringe
• 2–3 times daily, in a fasted state
• This is the most commonly discussed GH secretagogue protocol

Combined with CJC-1295 (with DAC)

• Ipamorelin: 200–300 mcg at bedtime (daily)
• CJC-1295 with DAC: 2 mg once or twice per week
• The DAC version provides sustained GHRH-level stimulation while ipamorelin adds acute GH pulses

Timing considerations

• Fasted state: GH release is reported to be blunted by food, particularly carbohydrates and fats. At least 2 hours after eating is commonly described.
• Bedtime injection: the most commonly recommended timing, described as amplifying the natural nocturnal GH surge
• Avoiding insulin spikes: insulin is the primary suppressor of GH release

Reconstitution

Ipamorelin is typically supplied as 2 mg or 5 mg lyophilized powder. Common reconstitution: 5 mg + 2.5 mL bacteriostatic water = 2,000 mcg/mL. Refrigerate after reconstitution; typically described as stable for 3–4 weeks. The peptide storage and reconstitution guide covers general preparation principles.

Side Effects and Safety Considerations

Ipamorelin has one of the milder side effect profiles among GH secretagogues, based on both clinical trial data and community reports.

Commonly reported side effects

• Head rush or mild headache: typically transient, more common in early use
• Water retention: mild, dose-dependent (a recognized GH class effect)
• Tingling or numbness: carpal tunnel-like symptoms at higher doses (GH class effect)
• Injection site reactions: consistent with subcutaneous injection generally
• Mild hunger increase: present but substantially less than with GHRP-6

Long-term considerations

IGF-1 elevation: Chronic GH elevation raises IGF-1, which has both anabolic/repair benefits and theoretical cancer concerns. Epidemiologically, high IGF-1 is associated with increased cancer risk, though the causal relationship is complex and context-dependent.

Insulin sensitivity: GH has anti-insulin effects. Prolonged use of any GH secretagogue may reduce insulin sensitivity, particularly at higher doses. This is a class effect, not specific to ipamorelin.

Pituitary desensitization: A theoretical concern with continuous use. Clinical evidence is limited, and the community standard of cycling (8–12 weeks on, followed by a break) is described as a precautionary measure.

What ipamorelin does not do (compared to other GHRPs)

This is the key differentiator:

• Does not cause significant cortisol release (unlike GHRP-6, GHRP-2)
• Does not cause significant prolactin elevation (unlike GHRP-2, hexarelin)
• Does not cause intense appetite stimulation (unlike GHRP-6)
• Does not desensitize as quickly as hexarelin is reported to

How Ipamorelin Relates to Other Peptides

• CJC-1295 (Mod GRF 1-29): the most commonly discussed pairing. CJC-1295 works on the GHRH receptor while ipamorelin works on the ghrelin receptor, creating synergistic GH release.
• Sermorelin: an alternative GHRH analog. Has a shorter half-life than CJC-1295 but a former FDA approval and more extensive human safety data. Can be combined with ipamorelin similarly.
• GHRP-6: an older ghrelin mimetic with stronger GH release but significant cortisol elevation and appetite stimulation. Less selective than ipamorelin.
• GHRP-2: another ghrelin mimetic, intermediate in selectivity between ipamorelin and GHRP-6.
• Hexarelin: a potent GHRP that reportedly desensitizes more quickly than ipamorelin.
• MK-677: an oral ghrelin mimetic. Convenient dosing but less selective than ipamorelin and with different pharmacokinetics.
• Tesamorelin: an FDA-approved GHRH analog with strong clinical data for visceral fat loss.
• BPC-157 — sometimes discussed alongside ipamorelin in recovery contexts, since GH elevation may support healing. See our injury recovery guide.

Legal Status

United States

Ipamorelin is not FDA-approved for any human use. It is available as a research chemical. Some anti-aging clinics prescribe it off-label, though this exists in a regulatory gray area. The FDA has issued guidance regarding compounded GH secretagogues.

Australia

Classified as Schedule 4 (prescription-only) by the TGA.

WADA

Prohibited under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). GH secretagogues are explicitly banned in competitive sports.

Frequently Asked Questions

How is ipamorelin different from HGH injections?

Ipamorelin stimulates the pituitary to produce and release its own GH, preserving natural pulsatile patterns and feedback mechanisms. Exogenous HGH bypasses the pituitary entirely, providing synthetic GH directly. Ipamorelin’s approach is generally considered more physiological, though exogenous GH allows more precise dosing and produces larger absolute GH elevations.

Does ipamorelin make you hungry?

Substantially less than GHRP-6. Ipamorelin’s selectivity means it does not strongly activate ghrelin’s appetite-stimulating pathway. Some mild hunger increase is reported, but it is generally described as manageable.

How long does it take to notice effects?

Community reports commonly describe improved sleep quality within the first 1–2 weeks. Body composition changes (lean mass, fat reduction) are typically reported over 4–8 weeks. Anti-aging effects are described as gradual over months.

Does ipamorelin suppress natural GH production?

Unlike exogenous GH, ipamorelin works through the body’s own release mechanisms. The pituitary still produces GH — ipamorelin signals it to release more in response to receptor activation. This is thought to be less suppressive than exogenous GH, though the long-term effects of chronic ghrelin-receptor stimulation on pituitary function have not been thoroughly studied.

How does ipamorelin compare to MK-677?

MK-677 is an oral ghrelin mimetic, convenient because it doesn’t require injection. However, MK-677 tends to produce more sustained GH elevation (rather than pulsatile), has a longer duration of action, and is generally considered less selective than ipamorelin. MK-677 is associated with more water retention, hunger stimulation, and potential insulin sensitivity effects than ipamorelin.

Can ipamorelin be used long-term?

The community standard is cycling (8–12 weeks on, followed by a break) as a precautionary measure against potential pituitary desensitization. Some report using it continuously with periodic blood work to monitor IGF-1 and metabolic markers. Long-term safety data beyond the clinical trial period is not available.

References

1. Raun K, et al. “Ipamorelin, the first selective growth hormone secretagogue.” Eur J Endocrinol. 1998;139(5):552-61. PubMed
2. Hansen BS, et al. “The growth hormone secretagogue ipamorelin: pharmacokinetics and pharmacodynamics in healthy volunteers.” Growth Horm IGF Res. 1999;9(5):313-9. PubMed
3. Greenwood-Van Meerveld B, et al. “The effect of ipamorelin, a ghrelin mimetic, on gastric and colonic motility in the dog.” Neurogastroenterol Motil. 2007;19(4):281-90. PubMed
4. Svensson J, et al. “The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats.” J Endocrinol. 2000;165(3):569-77. PubMed
5. Johansen PB, et al. “Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats.” Growth Horm IGF Res. 1999;9(2):106-13. [research needed]

Related Articles

Peptide

CJC-1295: What the Evidence Says About This GHRH Analog

An evidence-first review of CJC-1295, covering how it differs from native GHRH, DAC vs no-DAC variants, clinical trial data, and what the research shows about GH stimulation.

Peptide

GHRP-2: What the Research Shows About This Second-Generation GH Secretagogue

An evidence-based review of GHRP-2 — clinical data on growth hormone release, comparisons to GHRP-6 and ipamorelin, and safety considerations.

Peptide

Hexarelin: What the Research Shows About This Potent GH Secretagogue

An evidence-based review of hexarelin, covering research on growth hormone release, cardiac effects, desensitization concerns, and comparisons to other GHRPs.